Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026

Breakthrough in Cancer Immunotherapy: In Situ CAR-T Cell Generation Offers Hope for Lymphoma and Beyond
/in Immunotherapy, mRNA, Preclinical Research/by MaxA groundbreaking study led by Stanford Medicine, published in Cancer Immunology Research, has introduced a revolutionary approach to generating chimeric antigen receptor (CAR)-T cells directly inside the body, offering a promising new avenue for cancer treatment. This “in situ” method, which uses mRNA delivered via lipid nanoparticles (LNPs), successfully treated B-cell lymphoma in mice and […]
How Exercise Boosts Cancer Immunotherapy: The Role of Gut Microbes and Formate
/in Not PCa related/by MaxNew Combination Therapy Gets Fast Tracked: 177Lu-PSMA-617 (Pluvicto) Plus TRE-515
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dug Delivery Platform is Being Released
/in Delivery, Preclinical Research/by MaxNew Phase 3 Trial Approved for Masitinib for mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxKorean Team Unveils Breakthrough All-in-One Cancer Nanomedicine
/in Preclinical Research/by MaxIn a groundbreaking advancement for cancer treatment, a team from the Korea Research Institute of Standards and Science (KRISS) has developed an innovative nanomaterial that could transform cancer care. This “all-in-one” nanomedicine, known as gold-iron-gold nanodisks (AuFeAuNDs), integrates diagnosis, treatment, and immune activation into a single platform. Still in pre-clinical stages, this discovery shows significant […]
Early Results of Gedatolisib and Darolutamide in mCRPC Treatment
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: a New Phase 3 Trial for mCSPC
/in Clinical Trial, Metastatic, Phase 3/by Max